Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Deutsche Boerse AG  >  3SBio Inc. (ADR)    YFK

 SummaryQuotesNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ( CNY)
Sales 2016 2 894 M
EBIT 2016 921 M
Net income 2016 747 M
Debt 2016 1 275 M
Yield 2016 -
Sales 2017 3 658 M
EBIT 2017 1 180 M
Net income 2017 1 002 M
Debt 2017 367 M
Yield 2017 -
P/E ratio 2016 23,73
P/E ratio 2017 17,71
EV / Sales2016 6,53x
EV / Sales2017 4,92x
Capitalization 17 619 M
More Financials
Company
3SBio, Inc. operates as in investment holding company which engages in the development, production, marketing, and sale of biopharmaceutical products.It is used in the field of medicine particularly in nephrology, oncology, supportive cancer care, inflammation and infectious diseases.The company... 
Sector
Pharmaceuticals
Calendar
03/21Earnings Release
More about the company
Surperformance© ratings of 3SBio Inc. (ADR)
Trading Rating : Investor Rating :
More Ratings
Latest news on 3SBIO INC. (ADR)
10/12 3SBIO : granted exclusive license of diabetes drugs
10/11 3SBIO : AstraZeneca Ink Licensing Agreement
07/08 3SBIO : gets nod for colorectal cancer drug clinical trial
06/03 3SBIO INC. : (01530) says ITP drug get clinical trial approval
05/20 3SBIO INC. : (01530) withdraws breast cancer drug application
03/17 3SBIO : PEG-irinotecan Wins IND Approval From China FDA
03/04 3SBIO : Bought CNY3.9bn Shares in CPGJ
03/04 3SBIO : adds stake in CP Guojian Pharma at Rmb3.9bn
02/23 3SBIO : Wins Financing for Further Equity Investment
02/23 3SBIO : inks Rmb2.2bn term loan facility
More news
Sector news : Biopharmaceuticals
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
12/02DJJOHNSON & JOHNSON : Jury Orders Johnson & Johnson to Pay More Than $1 Billion in..
12/01DJValeant Deal Talks Collapse Over Price -- WSJ
12/01DJCSL : Eyes Biggest Undertaking Yet in Heart Therapy Trial
More sector news : Biopharmaceuticals
Advertisement
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 8,94  CNY
Spread / Average Target 28%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jing Lou Chairman, President & Chief Executive Officer
Wei hong Xiao Chief Operating Officer
Bo Tan Chief Financial Officer & Executive Director
Dong Mei Su Executive Director
Bin Huang Executive Director & Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
3SBIO INC. (ADR)0.00%2 560
BIOGEN INC-3.45%64 661
CSL LIMITED-5.78%33 156
ALEXION PHARMACEUTICAL..-35.54%27 574
BIOMARIN PHARMACEUTICA..-18.26%14 139
GRIFOLS SA-15.08%12 072
More Results